United Advisor Group’s Regeneron Pharmaceuticals REGN Stock Holding History

United Advisor Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$285K	Buy	376 +41	+12%	+$31K	0.03%	467
2026 Q2	$209K	Hold	335	–	–	0.02%	510
2026 Q1	$259K	Buy	335 +4	+1%	+$3.06K	0.03%	426
2025 Q4	$256K	Sell	331 -130	-28%	-$88.3K	0.03%	414
2025 Q3	$259K	Buy	461 +76	+20%	+$43K	0.03%	396
2025 Q2	$202K	Buy	385 +4	+1%	+$2.23K	0.03%	377
2025 Q1	$242K	Sell	381 -74	-16%	-$50.9K	0.05%	308
2024 Q4	$324K	Sell	455 -94	-17%	-$78.9K	0.06%	283
2024 Q3	$577K	Buy	549 +224	+69%	+$249K	0.13%	161
2024 Q2	$342K	Buy	325 +30	+10%	+$29.1K	0.11%	185
2024 Q1	$284K	Buy	+295	New	+$281K	0.11%	168

Other funds holding REGN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

United Advisor Group's REGN Position: Q3 2026 in Review

United Advisor Group increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q3 2026, buying an estimated $31K and bringing the position to 376 shares worth $285K. The position accounts for 0.03% of the portfolio, ranked #467.

United Advisor Group first reported a position in REGN in Q1 2024 and has held it in 11 quarters since. The position peaked at $577K in Q3 2024. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

United Advisor Group held 376 shares of Regeneron Pharmaceuticals worth $285K as of Q3 2026.
United Advisor Group bought 41 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $31K.
Regeneron Pharmaceuticals made up 0.03% of United Advisor Group's portfolio in Q3 2026, its #467 holding.
United Advisor Group first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
United Advisor Group's Regeneron Pharmaceuticals position peaked at $577K in Q3 2024.
1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on United Advisor Group's 13F filing for Q3 2026, filed 3 Nov 2026.